Prodia Subsidiary (PRDL) Sets IPO Price at Rp 120 per Share

PT Prodia Diagnostic Line has commenced its initial public offering (IPO) period today, Wednesday (1/7/2026). The prospective issuer, which will trade under the stock code PRDL, has set its offering price at Rp120.

This price represents the upper end of the Rp100-Rp120 per share offering range specified in the IPO prospectus. PRDL is offering up to 522.9 million new shares, equivalent to 30% of the placed and fully paid-up capital after the IPO. Through this move, the Prodia Group subsidiary intends to raise fresh funds of Rp62.75 billion.

From the total funds raised, approximately Rp35.67 billion will be utilised to settle principal loan obligations to PT Bank Central Asia Tbk. (BCA) and PT Bank Pan Indonesia Tbk. (Panin Bank).

Regarding financial performance, PRDL’s net profit reached approximately Rp35.8 billion in 2023, before dropping sharply to Rp10 billion in 2024, and subsequently recovering to around Rp17 billion in 2025.

PRDL is a company engaged in the manufacturing and processing of medical diagnostic equipment, specifically in vitro diagnostics (IVD). The company operates production facilities in the Jababeka III Industrial Estate, Cikarang, West Java.

The listing of PRDL shares on the Indonesia Stock Exchange (BEI) is scheduled for 9 July 2026.